Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Published:2023-06 Issue:3 Volume:8 Page:101216
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Wang Y.,Xu H.,Han Y.,Wu Y.,Sa Q.,Wang J.

Funder

Chinese Academy of Meteorological Sciences

Chinese Academy of Medical Sciences Cancer Institute and Hospital

Peking Union Medical College Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference53 articles.

1. Molecular portraits of human breast tumours;Perou;Nature,2000

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. Triple positive breast cancer: a distinct subtype?;Vici;Cancer Treat Rev,2015

4. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study;Vaz-Luis;Breast Cancer Res,2012

5. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;Perez;J Clin Oncol,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance;Drugs - Real World Outcomes;2024-06-16

2. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities;Biomedicine & Pharmacotherapy;2024-06

3. Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses;Frontiers in Oncology;2024-04-03